The time-dependent repression of cell viability induced by tamoxifen was attenuated by pretreatment with GF109203X, an inhibitor of PKC (Fig. 2B–F), which suggests that tamoxifen repressed pancreatic cancer cell viability in a PKC pathway-dependent manner. This evidence concerns the gene PRRT2 and pancreatic neoplasm.